Drug Shortage Report for IMIPENEM AND CILASTATIN FOR INJECTION USP

Last updated on 2023-10-27 History
Report ID 144424
Drug Identification Number 02358336
Brand name IMIPENEM AND CILASTATIN FOR INJECTION USP
Common or Proper name IMIPENEM AND CILASTATIN FOR INJECTION USP
Company Name SANDOZ CANADA INCORPORATED
Market Status MARKETED
Active Ingredient(s) CILASTATIN IMIPENEM
Strength(s) 250MG 250MG
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 10PSOIJ CA
ATC code J01DH
ATC description OTHER BETA-LACTAM ANTIBACTERIALS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-08-20
Estimated end date Unknown
Actual end date 2023-10-26
Shortage status Resolved
Updated date 2023-10-27
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 110 RUE DE LAUZON
BOUCHERVILLE, QUEBEC
CANADA J4B 1E6
Company contact information 1 800-361-3062

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2023-10-27 English Compare
v5 2023-10-26 French Compare
v4 2023-10-26 English Compare
v3 2023-10-26 English Compare
v2 2021-08-23 French Compare
v1 2021-08-23 English Compare

Showing 1 to 6 of 6